STENTiT is a Dutch MedTech company aiming to transform vascular reconstruction. Our innovative approach focuses on developing the Resorbable Fibrillated Scaffold (RFS), capable of triggering a natural healing response to reconstruct a newly grown artery from the inside out.

At STENTiT, we’re not just aiming to improve existing stenting methods; we’re redefining the entire landscape of endovascular treatments. We are initially focusing on addressing below-the-knee chronic limb threatening ischemia (CLTI), a pressing issue affecting 3.5 million patients in the EU and the US. With our RFS technology, we aim to provide patients with more effective treatments and save costs for society by preventing interventions and amputations.

However, our vision extends far beyond this initial focus. We believe that the unique properties of the RFS hold tremendous potential across a range of endovascular indications. STENTiT is at the forefront of transforming vascular reconstruction.